INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET® pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers.
INOVIQ’s headquarters are based in Melbourne, Australia, and we have representation in the USA with a dedicated team of 17 employees, including 10 R&D members who collectively hold 8 PhDs. Our expertise spans research, development, clinical testing, and commercialisation. The Company has facilities for cGMP production and is compliant with ISO17025.
INOVIQ is committed to developing next-generation precision diagnostics and exosome solutions that transform the diagnosis and treatment of cancer and other diseases to improve patient outcomes and save lives.
The Company was established in 2016, as has strategically grown through multiple acquisitions and in-licensing to expand our technology portfolio.